Jilin Aodong: Holding Subsidiary Taonan Pharmaceutical Obtains National Drug Standards for Calf Spleen Extract Injection

Jilin Aodong announced that its holding subsidiary Taonan Pharmaceutical received the "National Drug Standard Issuance" for "Bovine Spleen Extract Injection" issued by the National Medical Products Administration. The drug quality standard has been revised to include identification, high molecular weight substances, amino acids, osmotic pressure molar concentration, biological activity, bacterial endotoxins, hypotensive substances, peptide and ribose content determination items, and revised the quality standard for Bovine Spleen Extract Solution in Appendix 1, while also adding Appendices 2-6. The quality standard of this product will be implemented according to the revised standards from the date of implementation. Obtaining this issuance creates favorable conditions for the company's steady development, but the sales of the drug may be affected by factors such as changes in the market environment, which may bring uncertainties.